Top-News
Biotechnologie Deutschland

Vivoryon Therapeutics News

Aktie
WKN:  A2QJV6 ISIN:  NL00150002Q7 US-Symbol:  PRBGF
0,805 €
-0,038 €
-4,51%
16:52:31 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
24,11 Mio.
Marktkapitalisierung *
19,29 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 15.01.2024

Vivoryon Therapeutics News

15.05.24 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
08.05.24 - GlobeNewswire
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
24.04.24 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
16.04.24 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
15.03.24 - GlobeNewswire
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
04.03.24 - ARIVA.DE Redaktion
Vivoryon und der Rückschlag in der Alzheimer-Forschung: Ein detaillierter Blick auf die VIVIAD-Studie
Ein weiterer Rückschlag für die Alzheimer-​Forschung: Die VIVIAD-​Studie von Vivoryon Therapeutics konnte die gesetzten Ziele nicht erreichen. Was bedeutet dies für die Zukunft der ...
04.03.24 - GodmodeTrader
VIVORYON - Studienflop! Biotech-Aktie crasht über 80 %
04.03.24 - Der Aktionär
Vivoryon: Alzheimer‑Studie enttäuscht – Aktie bricht ein
04.03.24 - GlobeNewswire
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer ’ s Disease
08.01.24 - GlobeNewswire
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
06.12.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
28.11.23 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
07.09.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics N.V. Reports H1 202 3 Financial Results and Highlights Operational Progress
31.08.23 - GlobeNewswire
Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023
Vivoryon Therapeutics N.V. t o Report Half Year 202 3 Financial Results and Operational Progress on September 07 , 202 3
04.08.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023
Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board , Being H eld on September 15, 2023
04.08.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer
16.07.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-​Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease
21.06.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting
15.06.23 - GlobeNewswire
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
Vivoryon Therapeutics N.V. Announces CEO Transition Plan
01.06.23 - GlobeNewswire
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences

Newssuche

Videos

17.05.24 -2,19%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »